Press release
Autoimmune Disease Therapeutics Market Report Up to 2031
Download Exclusive Sample of Report @ https://www.visiongain.com/report/autoimmune-disease-therapeutics-market/#download_sampe_div
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. The surge in adoption of autoimmune disease therapeutics and rising prevalence of autoimmune disease are some of the factors driving the growth of Autoimmune Disease Therapeutics market.
COVID-19 Impact on the Global Autoimmune Disease Therapeutics Market
The Coronavirus disease (COVID-19) is new virulent disease, growing transmission and fatal outcome in the global population. The pandemic is conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), and are at high infectious risk as compared to the general population, due to overall impairment of immune system typical of autoimmune diseases combined with the iatrogenic effect developed by corticosteroids and immunosuppressive drugs. However, increasing awareness about the pathophysiology of SARS-CoV-2 infection, leads to contribute towards some anti-rheumatic drugs as potential option to treat & manage COVID-19.
Market Driver
Surge in adoption of autoimmune disease therapeutics
The Hydroxychloroquine (antimalarial drug) is used in lupus and rheumatoid arthritis & may be helpful in some patients with Sjögren's syndrome, enables to reduce the joint pain. The disease-modifying antirheumatic drugs (DMARDS) includes compounds such as sulfasalazine, indicated to use for Rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other auto-inflammatory conditions. The increasing adoption of various drugs corticosteroids such as prednisone or immunosuppressive agents like methotrexate (Rheumatrex), azathioprine (Imuran), mycophenolate (Cellcept) or cyclophosphamide (Cytoxan) are increasing g to treat diseases. Additionally, the researchers are evaluating rituximab (Rituxan) and other biological therapies to treat cases of Sjögren’s syndrome.
Increase in incidence of autoimmune disease
According to American College of Rheumatology, it is estimated in US about 50 million people of all ages and genders have arthritis or other rheumatic conditions. The rheumatoid arthritis (RA) is common type of autoimmune arthritis, caused due to improper functioning of immune system. The patient with Sjögren’s syndrome is healthy, however, associated with rare complications such as risk for cancer of the lymph glands (lymphoma).
Market Opportunity
Increasing presence of pipeline drug
The Corbus Pharma investigational drug lenabasum, significantly completed primary objective of a Phase 2 study, without any unfavorable outcomes associated with the drug. The lenabasum is oral synthetic endocannabinoid-mimetic, used in patients with diffuse cutaneous systemic sclerosis. However, the drug does not receive US Food and Drug Administration-approval to treat overall disease. The pipeline drug for autoimmune disorder is currently in development by manufacturers, offers opportunity for promising advanced drugs.
Get Detailed TOC @ https://www.visiongain.com/report/autoimmune-disease-therapeutics-market/#download_sampe_div
Significant advancement in therapeutics
The formation of the National Organization for Rare Diseases, the Orphan Drug Act, investment for orphan drug development, the formation of the National Institutes of Health Office of Rare Diseases, and the passage of orphan drug legislation by other countries enhance the market growth. The Division of Advanced Therapeutics program is the flagship clinical research program in arthritis and autoimmune disorders at the Rebecca MacDonald Centre for Arthritis & Autoimmune Disease. It enables to develop advance therapies for rheumatic diseases, osteoarthritis, and psoriatic arthritis. However, the advancement in therapeutics enables to improvise and manage autoimmune diseases and provided availability of various option to treat the diseases.
Competitive Landscape
ABBOTT Laboratories, Hoffmann-La Roche AG, Johnson and Johnson, Bio-Rad Laboratories, Inc., Pfizer, Inc, Bristol-Myers Squibb, GlaxoSmithKline PLC, Biogen Inc, Bayer AG, Merck & Co., Inc., Chugai Pharmaceutical Co. Ltd. are some of the key players contributing to the growth of the global Autoimmune Disease Therapeutics market. The market players are adopting new strategies to stay competitive in the global market such as new product developments, joint ventures, mergers and acquisitions, and geographical expansions.
For instance, In December 2018 Chugai Pharmaceutical Co., Ltd announced that it has the US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NMOSD). The NMOSD is a rare, lifelong, and debilitating autoimmune disease of the central nervous system characterized by inflammatory lesions in the optic nerves and spinal cord.
In March 2019, Roche announced that the European Commission has approved MabThera (rituximab) to treat moderate to severe pemphigus vulgaris, a rare condition characterised by progressive painful blistering of the skin or mucous membranes. The PV is a rare and potentially life-threatening blistering condition which can cause severe pain and disfigurement.
Request Customized Report as Per Your Requirements @ https://www.visiongain.com/contact/
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Autoimmune Disease Therapeutics Market and leading companies. You will find data, trends and predictions.
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: catherine.walker@visiongain.com
Catherine Walker
PR at Visiongain Inc.
Tel: + 44 0207 336 6100
USA Tel: + 1 718 682 4567
EU Tel: + 353 1 695 0006
Toll Free: 00-1-646-396-5129
Email: catherine.walker@visiongain.com
Research Insight : https://www.visiongain.com/autoimmune-disease-therapeutics-market-analysis/
About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Autoimmune Disease Therapeutics Market Report Up to 2031 here
News-ID: 2418711 • Views: …
More Releases from Visiongain Pharma
Women’s Health Diagnostics Market Report to 2031
Visiongain has published a new report on Women’s Health Diagnostics Market Report to 2031: Forecasts by Application (Breast Cancer Testing (Mammography Systems, Breast Cancer Tumor Marker Tests. Blood Chemistries and Blood Cell Count, Biopsies, and Other Diagnostic Imaging Tests), Infectious Disease Testing (Urinary Tract Infection Testing, MRSA Testing, Hepatitis Testing, Tuberculosis Testing, and Other Infectious Disease Testing), Cervical Cancer Testing (Pap Smear and HPV Testing), Osteoporosis Testing (Bone Densitometry and…
Animal Hormones Market Report Up to 2031
Visiongain has published a new report on Animal Hormones Market Report to 2031: Forecasts By Application (Growth Promoters, Performance Enhancers, and Others), By Animal (Poultry, Porcine, Livestock, Equine, Aquaculture, and Other Animals (Cats, Dogs, & Rabbits)) PLUS COVID-19 Recovery Scenarios.
Download Exclusive Sample of Report @ https://www.visiongain.com/report/animal-hormones-market/#download_sampe_div
COVID-19 Impact on Animal Hormones Market
The COVID-19 pandemic has deleteriously affected all the countries and industries. Similarly, the animal hormones market is anticipated to take…
Animal Antimicrobials and Antibiotics Market Report Up to 2031
Visiongain has published a new report on Animal Antimicrobials and Antibiotics Market Report to 2031: Forecasts By Product Type (Penicillin, Tetracycline, Sulfonamides, Quinolones, Macrolides, Cephalosporin, Amingoglycoside, and Others), By Animal Type (Companion Animals and Food-producing Animals), By Mode of Delivery (Oral powder or solutions, Injections, Premix, and Others) PLUS COVID-19 Recovery Scenarios.
COVID-19 Impact on Animal Antimicrobials and Antibiotics Market:
The COVID-19 pandemic has deleterious affected all the countries and industries. Similarly,…
Angioplasty Balloons Market Report Up to 2031
Visiongain has published a new report on Angioplasty Balloons Market Report to 2031: Forecasts By Product Type (Normal, Drug-Eluting, and Cutting & Scoring Balloons), By Application (Coronary Artery Disease and Peripheral Artery Diseases) PLUS COVID-19 Recovery Scenarios.
How has COVID-19 Impacted on Angioplasty Balloons Market
COVID-19 pandemic adversely affected over 200 countries worldwide. Companies have been pressured to upsurge production capacity and raise the supply of products and other commodities. The pandemic…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
